Screening for Atrial Fibrillation in Patients With Cancer: A Pilot Randomized Controlled Clinical Trial
NCT ID: NCT05784766
Last Updated: 2023-11-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
480 participants
INTERVENTIONAL
2023-11-06
2025-07-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Screen group
Patients randomized to screening will undergo a 30-second ECG using the Kardia Mobile device (AliveCor Inc, Cupertino, CA) paired with an iPad (Apple, Cupertino, CA). If the mobile ECG shows possible AF or unclassified, then patients will undergo a 12-lead standard ECG during the same visit, read by a cardiologist, to verify the correct diagnosis.
30-second ECG using the Kardia Mobile
30-second ECG using the Kardia Mobile
Usual Care
For patients in the usual care arm, medical record review will be done at end of study to assess for the newly diagnosed AF during the study period.
routine care
medical review
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
30-second ECG using the Kardia Mobile
30-second ECG using the Kardia Mobile
routine care
medical review
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients currently undergoing or history of chemotherapy, radiotherapy or cancer related surgeries will be included.
3. The age is restricted to ≥65 years because prevalence of AF is extremely low. .
Exclusion Criteria
2. Non-English-speaking participants will not be enrolled
65 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Oklahoma
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Zain Asad, MD
Role: PRINCIPAL_INVESTIGATOR
OU Health
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Aurora Vera
Role: primary
Natalia Serrano
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
15595
Identifier Type: -
Identifier Source: org_study_id